September 29 edition: uniQure's four-year Huntington's readout is mixed, while its filing rests on earlier data. AstraZeneca agrees to invest $2 billion in Summit alongside a cancer-combination program, without acquiring Summit's drug rights. In the roundup: Veracyte's retrospective Decipher analysis in prostate cancer; FDA approval of Teva's Xgeva biosimilar; and Novo's license to Hengrui's early oral GLP-1/GIP program. Invivyd reports tolerability, not protection,

We've all felt a pang of envy watching a friend's success or a colleague's promotion. But does this much-maligned emotion deserve its negative reputation? Psychologist Jens Lange, PhD, and philosopher Sara Protasi, PhD, discuss the difference between envy and jealousy; why we're often most envious of the people closest to us; and how envy may, in the right circumstances, motivate us to grow.Learn more about your ad choices. Visit megaphone.fm/adchoices

Today Mary is joined by Stacey Berger, a beauty industry veteran with more than 25 years of experience developing and manufacturing skincare and haircare across clinical and mass-market beauty.Stacey shares what she discovered about the dramatic changes women's skin can experience during perimenopause and post-menopause, and why traditional skincare approaches may not address the hormonal shifts happening beneath the surface.The conversation explores the seven interconnected shifts that can

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.

If you, like us, clicked on the cute cat photos posted everywhere recently, announcing the discovery of the first new cat species in more than a century, you might have wondered how rare it is to find a new species. Turns out, it’s not! We live in an era of “unprecedented” discovery, says John Wiens, a professor of ecology and evolutionary biology at the University of Arizona. And scientists say we’re still just scratching at the surface of how much life exists on Earth.   Interested in more science

Many cancer treatments fail not because immune cells can’t recognize a tumor, but because the hostile environment surrounding it can prevent them from doing their job. Dyve Biosciences is seeking to address that problem by targeting tumor acidity, which the company says can suppress T-cell activity, promote immune evasion, and contribute to resistance to checkpoint inhibitors and other therapies. Its solution is a transdermal drug-delivery platform designed to move a buffering agent through the skin

In this episode of Behind the Genes, we explore Black communities and health research. Our guests discuss why some people feel research is not intended for them, how historical mistrust affects participation, and what needs to change to make research more inclusive, transparent and beneficial for everyone. Our host, Sharon Jones, is joined by: Professor Segun Fatumo - Professor and Chair of Genomic Diversity at Queen Mary's Hospital Christella Matoko - Project manager at Genomics

Key developments from Johnson & Johnson, Ultragenyx, Abogen Biosciences, and Daiichi Sankyo.

Better Patient Centricity by Adoption of Emerging Technologies What if healthcare could move beyond simply treating illness after it appears—and instead continuously help people predict, prevent, and manage their health? In this episode of Center of Excellence - Pharma 4.0, we explore how emerging technologies are transforming healthcare from a predominantly reactive, episodic model into a proactive, personalised, connected, and patient-centric ecosystem. The traditional healthcare experience often

It’s horror movie night, but Heather can’t stop seeing infectious disease in the monsters.Heather is joined by her friend Valerie to explore the real biology behind some of horror’s most enduring fears: tuberculosis and vampire lore, rabies and werewolves, zombies as outbreak epidemiology, neurological disease and possession, and the strange biology behind The Last of Us, The Thing, and Alien. Plus, Valerie plays the hilarious Horror Movie or Medical Literature? and discovers that when it comes to

Extinction requires far more than protecting habitat alone.

March of Dimes Ohio Collaborative Prematurity Research Center coordinating principal investigator and Cincinnati Children’s Hospital infectious disease pediatrician Dr. Sing Sing Way discusses his team's new findings linking the use of mouthwash in pregnancy with dramatically reduced rates of preeclampsia, preterm birth, and chorioamnionitis.

This week we discuss a bright orange toxic gummy lizard — we do not advise consumption of this salamander.

Clinical traceability is about being able to follow evidence from a reported result back to its source and understand the transformations, decisions, and records in between. In this QCast episode, co-hosts Jullia and Tom discuss how traceability can become harder when studies involve multiple systems, CROs, laboratories, and technology providers, and why retaining files alone is not enough.Key TakeawaysStrong traceability connects reported results with the underlying data, derivations, programs, and

Send us Fan MailProstate cancer: PSA, ADT, Gleason and Pluvicto explained live by a cancer drug designer. LIVE was filmed on 9/14/26. 👉 Get your free guide, '10 Things to Elevate Your Chemo Journey'👉 Want personalized attention to help you along your individual cancer journey? Explore 1:1 sessions with Dr. Chaplin👉 Want to find out more about Dr. Chaplin's journey of bringing a cancer drug to market? Explore his innovations--------------------------------------------Episode

In this episode of the Biohacker's Podcast, Teemu Arina speaks with Don Diablo on fear as fuel, discipline, fasting and building a creative legacy.Check https://hololifesummit.com for upcoming events & tickets.Devices, supplements, guides, books & quality online courses for supporting your health & performance: https://hololifecenter.comDon Diablo, DJ, producer, artist and founder of HEXAGONDon Diablo is a Dutch DJ, producer and multidisciplinary artist who released his first record

For decades, scientists pursued one goal: a vaccine that could prevent the disease. But malaria is caused by a complex parasite, making vaccine development far more challenging than for most infectious diseases. One scientist dedicated his career to this challenge. Sir Adrian Hill of the University of Oxford witnessed children dying from malaria in Gambia in the late 1980s and set out to develop a vaccine that could save lives where it was needed most. For this work, he received the European

Each week, join Editor-in-Chief Brad Maron, along with cohosts Mercedes Carnethon and Jane Wilcox for the new iteration of Circulation on the Run. This week, Brad and Jane welcome author Alexis F. Guédon to discuss his article "Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis." Then Deputy Editor Joseph C. Wu joins the podcast to discuss his Research Letter "Modeling Heart Failure With Preserved Ejection Fraction Using Human Induced

We can learn about horticulture from slides in a classroom, sure. But everything changes when the classroom is perhaps Rome, or the lab is a botanic garden in Scotland, and the homework might be noticing what’s growing on the hills and valleys outside the bus window. In this episode, our co-host, Curt Rom, talks with Co-Host Samson Humphrey about the value of studying abroad and how it can make the world feel bigger and smaller at the same time - something that Curt has learned not only from ...